CHF Solutions Submits Patent Application for New and Improved Diagnostic Parameters to Support Hemodynamic Stability
February 03 2021 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced the submission of a patent application to increase
monitoring capabilities with its Aquadex SmartFlow™ system. The new
technology is intended to provide clinicians with additional
patient output data to inform treatment approaches and improve
patient outcomes.
Aquadex SmartFlow currently provides critical patient
information to assist clinicians in the precise delivery of
ultrafiltration therapy. The new innovations included in this
patent application will improve key diagnostic information to
support hemodynamic stability in patients. The non-invasive
technology provides accurate and more timely cardiovascular
parameters for metrics such as systemic vascular resistance and
hematocrit in an intuitive presentation.
“At CHF Solutions, we continue to invest in technological
advancements that have a meaningful impact for patients and
clinicians,” said Nestor Jaramillo, Jr., President and CEO
of CHF Solutions. “Clinicians rely on us to provide intuitive
technology that helps them make the smartest decisions for their
patients, which is why we continuously work on improvements that
expand capabilities and foster confidence in our ultrafiltration
therapy. This patent application is the first step to offering new
and improved metrics that indicate a change in the fluid management
approach may be warranted.”
Fluid overload is a major issue among critically ill children
and adults and contributes to increased length of hospitalizations
and readmissions.1 Ultrafiltration with Aquadex™ is associated
with a higher cumulative fluid loss, higher net fluid loss and
greater relative reduction in body weight when compared to
pharmacologic therapy.2
About CHF Solutions CHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to improving the lives of patients suffering from fluid
overload with its novel ultrafiltration therapy system. The company
is focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the
benefits of innovations contained in the patent application.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
1 Costanzo MR et al. JACC. 2017;69(19):2428-45.
2 Grodin, J et al. European Journal of Heart Failure, 2018;
20(7), 1148-1156.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
Matt Bacso, CFA
Gilmartin Group LLC
Matt.bacso@gilmartinir.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024